# A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

> **NCT07107490** · PHASE1 · RECRUITING · sponsor: **Chugai Pharmaceutical** · enrollment: 122 (estimated)

## Conditions studied

- Extensive Stage Small Cell Lung Cancer

## Interventions

- **DRUG:** ALPS12
- **DRUG:** obinutuzumab

## Key facts

- **NCT ID:** NCT07107490
- **Lead sponsor:** Chugai Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-08
- **Primary completion:** 2028-09-30
- **Final completion:** 2028-09-30
- **Target enrollment:** 122 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07107490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07107490, "A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07107490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*